1-55058538-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 5P and 4B. PM1PM5PP3BS2
The NM_174936.4(PCSK9):c.1394C>T(p.Ser465Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000753 in 1,459,884 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S465W) has been classified as Likely pathogenic.
Frequency
Consequence
NM_174936.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PCSK9 | NM_174936.4 | c.1394C>T | p.Ser465Leu | missense_variant | 9/12 | ENST00000302118.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PCSK9 | ENST00000302118.5 | c.1394C>T | p.Ser465Leu | missense_variant | 9/12 | 1 | NM_174936.4 | P2 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251370Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135888
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1459884Hom.: 0 Cov.: 85 AF XY: 0.00000826 AC XY: 6AN XY: 726246
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
Likely pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Sep 29, 2023 | Published functional studies demonstrate a damaging effect through defective PCSK9-LDL binding (Sarkar et al., 2022); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Reported in association with FH in published literature (Sturm et al., 2021; Hopkins et al., 2015; Di Taranto et al., 2017; Ruotolo et al., 2014); This variant is associated with the following publications: (PMID: 29259136, 32058034, 26165249, 26374825, 29127338, 24607922, 31653860, 34037665, 36187800) - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Hypercholesterolemia, autosomal dominant, 3 Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 03, 2024 | This missense variant replaces serine with leucine at codon 465 of the PCSK9 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Functional studies have shown that this variant may cause a decrease in PCSK9 secretion and noted that this finding is not consistent with reported high LDL-C levels (PMID: 29259136, 32058034). Another functional study in transfected HEK293 cells has shown that this variant significantly decreased LDL binding (PMID: 36187800). This variant has been reported in two related individuals affected with hypercholesterolemia (PMID: 24607922). Cells from these carriers showed partially reduced LDLR activity but no change in the amount of LDLR protein at the cell surface. This variant has been reported in over ten unrelated individuals affected with hypercholesterolemia who showed mildly elevated LDL-C levels (PMID: 29127338, 26374825, 34037665; Color internal data). This variant has also been identified in 6/251370 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, the role of this variant cannot be determined conclusively, due to the unclear impact of this variant on the LDLR function and the observation of this variant in the general population. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 10, 2023 | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 465 of the PCSK9 protein (p.Ser465Leu). This variant is present in population databases (no rsID available, gnomAD 0.006%). This missense change has been observed in individuals with hypercholesterolemia (PMID: 24607922, 26374825). ClinVar contains an entry for this variant (Variation ID: 403292). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PCSK9 protein function. For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | May 03, 2023 | Criteria applied: PS4_SUP - |
Familial hypercholesterolemia Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 18, 2023 | This missense variant replaces serine with leucine at codon 465 of the PCSK9 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Functional studies have shown that this variant may cause a decrease in PCSK9 secretion and noted that this finding is not consistent with reported high LDL-C levels (PMID: 29259136, 32058034). Another functional study in transfected HEK293 cells has shown that this variant significantly decreased LDL binding (PMID: 36187800). This variant has been reported in two related individuals affected with hypercholesterolemia (PMID: 24607922). Cells from these carriers showed partially reduced LDLR activity but no change in the amount of LDLR protein at the cell surface. This variant has been reported in over ten unrelated individuals affected with hypercholesterolemia who showed mildly elevated LDL-C levels (PMID: 29127338, 26374825, 34037665; Color internal data). This variant has also been identified in 6/251370 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, the role of this variant cannot be determined conclusively, due to the unclear impact of this variant on the LDLR function and the observation of this variant in the general population. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Ser465Leu variant in PCSK9 has been reported in 13 individuals with familial hypercholesterolemia, segregated with disease in 2 affected relatives from 1 family (PMID: 24607922, 26374825, 29127338), and has been identified in 0.005% (1/18392) of East Asian chromosomes and 0.004% (4/113662) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs778849441). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported in ClinVar as a VUS, likely pathogenic, and pathogenic (Variation ID#: 403292). Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Ser465Leu variant is uncertain. ACMG/AMP Criteria applied: PS4_moderate, BP4 (Richards 2015). - |
Hypercholesterolemia, familial, 1 Pathogenic:1
Pathogenic, no assertion criteria provided | research | Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum | - | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 31, 2017 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: 2 papers, not sig diff LDLR - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at